Sai Life Sciences Limited has informed the Exchange regarding a press release dated May 14, 2025, titled "Press release for the Financial Results for the quarter and year ending 31st March 2025".
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences, a Hyderabad-based CRDMO (Contract Research, Development and Manufacturing Organization), reported strong FY25 results with revenue growing 16% year-on-year to ₹1,695 crore (vs ₹1,465 crore in FY24). EBITDA rose 42% to ₹425 crore, with margins expanding from 20% to 25%, and net profit (PAT) more than doubled to ₹170 crore (up 105% from ₹83 crore in FY24). In Q4FY25 alone, revenue grew 32% to ₹580 crore and PAT jumped 57% to ₹88 crore. The company completed ₹720 crore of planned debt repayment, expects lower interest costs in FY26, and spent ₹408 crore on capex focused on manufacturing and discovery capabilities. Management highlighted the launch of a new Peptide Research Centre and continued momentum across its CDMO and CRO segments.
Strong double-digit revenue growth, expanding margins, and over 100% PAT growth signal robust business momentum, likely to be viewed positively by investors. The debt repayment and lower interest costs in FY26 should further support profitability and strengthen the balance sheet.